Arcus Biosciences (RCUS) | Stock Overview & Key Data
Arcus Biosciences Performance Comparison
Stock Range
Today's Range
Low: $11.44
High: $11.84
on September 12, 2025
52 Week Range
Low: $6.50
High: $18.98
on April 7, 2025
on November 11, 2024
All-Time High: $49.10 on November 22, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.2B
EPS
-3.14
P/E Ratio (TTM)
-3.67
Forward P/E
-2.47
P/B Ratio
2.23
PEG Ratio
0.04
Div. Yield
N/A
ROE
-50.34%
Beta
0.825
Debt to Equity
23.68
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-5.00%
Profit Margin
-113.74%
Returns and Earnings
Return on Assets (TTM)
-18.69%
Return on Equity (TTM)
-50.34%
EBITDA
$-328.0M
Net Income (TTM)
$-298.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$2.84
Quarterly Revenue Growth (YoY)
310.30%
Quarterly Earnings Growth (YoY)
310.26%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Arcus Biosciences RCUS | 1.23B Small-cap | -5.50% | 19.13% | 23.21% | 18.76% | -23.86% | -35.82% | -55.56% | -47.49% |
| Vertex VRTX | 101.15B Large-cap | -0.40% | 1.74% | -14.24% | -20.36% | -2.77% | -18.72% | 36.18% | 48.66% |
| Alnylam ALNY | 61.07B Large-cap | 3.07% | 8.36% | 52.92% | 92.18% | 99.42% | 75.61% | 118.70% | 252.21% |
| Adaptive ADPT | 1.92B Small-cap | -1.87% | -0.39% | 21.13% | 65.49% | 103.72% | 173.54% | 65.27% | -72.79% |
| Dyne Therapeutics DYN | 1.87B Small-cap | -7.52% | 13.17% | -9.06% | 6.39% | -48.35% | -61.39% | -3.66% | -42.32% |
| Harmony Biosciences HRMY | 1.86B Small-cap | -10.00% | -8.68% | -2.82% | -3.60% | -7.01% | -16.76% | -26.12% | -3.60% |
Ownership & Short Interest
Insider Ownership
34.73%
Institutional Ownership
67.52%
Shares Short
10M
Short Ratio
13.27
Short % of Shares Outstanding
14.13%
Average 10-Day Volume
863K
Average 90-Day Volume
794K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is RCUS's 52-week high and low?
- In the last 52 weeks, Arcus Biosciences reached a high of $18.98 (on November 11, 2024) and a low of $6.50 (on April 7, 2025).
- What is the market cap and P/E ratio for RCUS?
- Curious about Arcus Biosciences's size and valuation? Its market capitalization stands at 1.23B. When it comes to valuation, the P/E ratio (trailing twelve months) is -3.67, and the forward P/E (looking ahead) is -2.47.
- Does RCUS pay dividends? If so, what's the yield?
- As for dividends, Arcus Biosciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Arcus Biosciences's main competitors or similar companies to consider before investing?
When looking at Arcus Biosciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.15B Healthcare Biotechnology -18.72% 36.18% Alnylam
ALNY61.07B Healthcare Biotechnology 75.61% 118.70% Adaptive
ADPT1.92B Healthcare Biotechnology 173.54% 65.27% Dyne Therapeutics
DYN1.87B Healthcare Biotechnology -61.39% -3.66% Harmony Biosciences
HRMY1.86B Healthcare Biotechnology -16.76% -26.12% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Arcus Biosciences Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Arcus Biosciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -50.34%, the Debt to Equity ratio from the most recent quarter is 23.68, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for RCUS?
- Looking at Arcus Biosciences's growth, its revenue over the trailing twelve months (TTM) was $262M. Compared to the same quarter last year (YoY), quarterly revenue grew by 310.30%, and quarterly earnings saw a YoY growth of 310.26%.
- How much of RCUS stock is held by insiders and institutions?
- Wondering who owns Arcus Biosciences stock? Company insiders (like executives and directors) hold about 34.73% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 67.52%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.